Summary: Trudell Medical Limited is set to acquire the RDx business unit from Vyaire Medical, expanding its market in respiratory diagnostics. The acquisition will maintain RDx’s operations in Germany and California, ensuring continued service for RDx customers.

Key Takeaways:

  • Expansion of Market Position: The acquisition will broaden Trudell Medical’s reach in respiratory diagnostics.
  • Continued Operations: RDx will continue operating as a separate unit in Germany and California.
  • Court Approval Pending: The purchase is expected to close in 8-12 weeks, subject to court approval.

Trudell Medical Limited has reached an agreement to purchase the RDx business unit of Vyaire Medical.

Focus on Respiratory Diagnostics

RDx manufactures respiratory diagnostic products that are used in hospitals and private clinics.

The purchase is subject to court approval and is expected to close in 8-12 weeks. The acquisition will expand Trudell Medical’s market position in aerosol drug delivery and lung health devices to include respiratory diagnostics.

RDx to Operate Independently

Trudell Medical intends to operate RDx as a separate business unit and maintain operations in Germany and California.

The acquisition would ensure the continuation of service to RDx customers. Earlier this year, Vyaire Medical filed for Chapter 11 Protection and announced the company was focused on selling its business units to stable, well-capitalized buyers.

Existing Partnership with Trudell Healthcare Solutions

Vyaire’s Respiratory Diagnostics and Ventilation solutions are currently distributed by Trudell Healthcare Solutions (THS) within the Canadian healthcare system.

“We welcome the opportunity to add Vyaire RDx’s people, products, and passion to our Trudell Medical family. Respiratory Diagnostics help to enhance and extend lives,” said George Baran, executive chair, Trudell Medical Limited. “This is in perfect alignment with our ‘Patient First’ Core Value across the Trudell Medical Group. Every day, we’re focused on designing and manufacturing products and services that improve patients’ lives.”